These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35609369)

  • 1. Impact of route-dependent phase-II gut metabolism and enterohepatic circulation on the bioavailability and systemic disposition of resveratrol in rats and humans: A comprehensive whole body physiologically-based pharmacokinetic modeling.
    Han DG; Seo SW; Choi E; Kim MS; Yoo JW; Jung Y; Yoon IS
    Biomed Pharmacother; 2022 Jul; 151():113141. PubMed ID: 35609369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
    Seo SW; Han DG; Choi E; Park T; Byun JH; Cho HJ; Jung IH; Yoon IS
    Biomed Pharmacother; 2022 Feb; 146():112520. PubMed ID: 34902744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model.
    Marier JF; Vachon P; Gritsas A; Zhang J; Moreau JP; Ducharme MP
    J Pharmacol Exp Ther; 2002 Jul; 302(1):369-73. PubMed ID: 12065739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model.
    Pang KS; Chow EC
    Drug Metab Dispos; 2012 Oct; 40(10):1869-77. PubMed ID: 22745334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical characterization and phase II metabolic profiling of echinochrome A, a bioactive constituent from sea urchin, and its physiologically based pharmacokinetic modeling in rats and humans.
    Han DG; Kwak J; Choi E; Seo SW; Vasileva EA; Mishchenko NP; Fedoreyev SA; Stonik VA; Kim HK; Han J; Byun JH; Jung IH; Yun H; Yoon IS
    Biomed Pharmacother; 2023 Jun; 162():114589. PubMed ID: 37004327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolite Kinetics: The Segregated Flow Model for Intestinal and Whole Body Physiologically Based Pharmacokinetic Modeling to Describe Intestinal and Hepatic Glucuronidation of Morphine in Rats In Vivo.
    Yang QJ; Fan J; Chen S; Liu L; Sun H; Pang KS
    Drug Metab Dispos; 2016 Jul; 44(7):1123-38. PubMed ID: 27098743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.
    Shirota K; Kaneko M; Sasaki M; Minato K; Fujikata A; Ohta S; Hisaka A; Suzuki H
    Drug Metab Dispos; 2015 Feb; 43(2):217-26. PubMed ID: 25422274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption and enterohepatic circulation of baicalin in rats.
    Xing J; Chen X; Zhong D
    Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach.
    Teeguarden JG; Waechter JM; Clewell HJ; Covington TR; Barton HA
    Toxicol Sci; 2005 Jun; 85(2):823-38. PubMed ID: 15746009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptotics and bioavailability in a 17-compartment pharmacokinetic model with enterohepatic circulation and remetabolization.
    Horkovics-Kovats S; Zlatos P
    Math Biosci; 2006 Sep; 203(1):19-36. PubMed ID: 16616213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children.
    Zane NR; Thakker DR
    Clin Pharmacokinet; 2014 Dec; 53(12):1171-82. PubMed ID: 25245942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate.
    Korzekwa K; Nagar S; Clark D; Sciascia T; Hawi A
    Mol Pharm; 2024 Sep; 21(9):4510-4523. PubMed ID: 38956965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.
    Roberts MS; Magnusson BM; Burczynski FJ; Weiss M
    Clin Pharmacokinet; 2002; 41(10):751-90. PubMed ID: 12162761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling.
    Toshimoto K; Tomoda Y; Chiba K; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2727-2738. PubMed ID: 28479365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the factors responsible for the low oral bioavailability of alizarin using a sensitive LC-MS/MS method: In vitro, in situ, and in vivo evaluations.
    Seo SW; Han DG; Baek YM; Park MC; Yoo JW; Jung Y; Maeng HJ; Myung H; Yoon IS
    Drug Dev Res; 2023 May; 84(3):579-591. PubMed ID: 36811607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.
    Moriwaki T; Yasui H; Yamamoto A
    J Pharmacokinet Pharmacodyn; 2003 Apr; 30(2):119-44. PubMed ID: 12942684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.